J. Goldman & CO LP Viking Therapeutics, Inc. Call Options Transaction History

J. Goldman & CO LP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$49.84 - $70.47 $672,840 - $951,345	-13,500 Reduced 40.3%	20,000 $1.27 Million
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $1.59 Million - $2.69 Million	33,500 New	33,500 $1.78 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $282,336 - $975,720	103,800 New	103,800 $975,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.